Citadel Advisors
TARS icon

Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673K Buy
10,700
+7,500
+234% +$479K ﹤0.01% 9173
2026
Q1 		$224K Buy
+3,200
New +$224K ﹤0.01% 11174
2025
Q2 		– Sell
-7,600
Closed -$390K – 15023
2025
Q1 		$390K Sell
7,600
-21,800
-74% -$1.08M ﹤0.01% 9016
2024
Q4 		$1.63M Buy
29,400
+25,300
+617% +$1.15M ﹤0.01% 6062
2024
Q3 		$135K Buy
4,100
+2,400
+141% +$67.5K ﹤0.01% 10697
2024
Q2 		$46.2K Sell
1,700
-20,600
-92% -$693K ﹤0.01% 11850
2024
Q1 		$811K Buy
22,300
+15,100
+210% +$444K ﹤0.01% 7376
2023
Q4 		$146K Buy
7,200
+7,000
+3,500% +$117K ﹤0.01% 10434
2023
Q3 		$3.55K Sell
200
-3,500
-95% -$61.9K ﹤0.01% 13572
2023
Q2 		$66.9K Buy
3,700
+1,300
+54% +$20.7K ﹤0.01% 11457
2023
Q1 		$30.2K Buy
2,400
+2,200
+1,100% +$32.2K ﹤0.01% 12736
2022
Q4 		$2.93K Buy
+200
New +$3.31K ﹤0.01% 14268

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's TARS Position: Q2 2026 in Review

Citadel Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 47% in Q2 2026, buying an estimated $4.97M and bringing the position to 241,737 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 16 quarters since. The position peaked at $51M in Q1 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Citadel Advisors held 241,737 shares of Tarsus Pharmaceuticals worth $15.2M as of Q2 2026.
  • Citadel Advisors bought 77,740 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.97M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2941 holding.
  • Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.